Get started
Author

Mayuri Mutukuru

Observed name: Mutukuru Mayuri
ORCID: 0000-0002-6265-4902
Observed ORCID: 0000-0002-6265-4902
OpenAlex ID: A5014641558
Cutting edge therapies: A review of Food and Drug Administration‐ approved drugs for non‐small cell lung cancer
2026 · Mutukuru Mayuri, Swathi Reddy Kandula, et al. · International Journal of Cancer · 5
NK1 receptor antagonistic effect of 17-trifluoromethyl phenyl trinor prostaglandin F2α on the growth of human breast cancer cell line
2022 · Mutukuru Mayuri, Praveen T. Krishnamurthy, et al. · Experimental and Molecular Pathology · 4
A comprehensive review on neurokinin-1 receptor antagonism in breast cancer
2021 · Mutukuru Mayuri, Thangavel Mahalingam Vijayakumar · Journal of Applied Pharmaceutical Science · 3
PDF
Substance P/NK1R Antagonistic Effect of 17-Trifluoromethyl Phenyl Trinor Prostaglandin F2α in Breast Cancer
2022 · Mayuri Mutukuru, T. M. Vijayakumar · International Journal of Peptide Research and Therapeutics · 2
PDF
Works count: 4
Citation count: 14
H-index: 3
I10-index:
Year
Topic
Type